Skip to content

Study · Not a test of the peptide alone · 2024

2 results

A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?

Docimo S Jr, Shah J, Warren G, Ganam S, Sujka J, DuCoin C

Surgical endoscopy16 Sept 2024Cited by 32 (Europe PMC)

PMID39285034 (opens in a new tab)DOI10.1007/s00464-024-11191-1 (opens in a new tab)PepBankPUB-39285034
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneObservational studyOther

    In a retail price analysis, ongoing Saxenda use cost more than Roux-en-Y gastric bypass in under a year and more than sleeve gastrectomy within nine months.

    In plain wordsBy retail prices, taking Saxenda long term cost more than gastric bypass after under a year and more than sleeve gastrectomy within nine months.

    Peptide
    Liraglutide
    Outcome
    Not applicableBreak-even cost versus bariatric surgery
    Study

    n: not reported in source

    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The findings revealed a crucial insight, for some GLP-1 s like Saxenda and Wegovy, the high cost of ongoing use surpasses the cost of RYGB in less than a year and sleeve gastrectomy within nine months.
    1 context sentence
    Summary · context
    We compared average 2023 national retail prices for GLP-1 s to surgical cost estimates from 2015 adjusted for inflation.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Semaglutide aloneObservational studyOther

    In a retail price analysis, ongoing Wegovy use cost more than Roux-en-Y gastric bypass in under a year and more than sleeve gastrectomy within nine months.

    In plain wordsBy retail prices, taking Wegovy long term cost more than gastric bypass after under a year and more than sleeve gastrectomy within nine months.

    Peptide
    Semaglutide
    Outcome
    Not applicableBreak-even cost versus bariatric surgery
    Study

    n: not reported in source

    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The findings revealed a crucial insight, for some GLP-1 s like Saxenda and Wegovy, the high cost of ongoing use surpasses the cost of RYGB in less than a year and sleeve gastrectomy within nine months.
    1 context sentence
    Summary · context
    We compared average 2023 national retail prices for GLP-1 s to surgical cost estimates from 2015 adjusted for inflation.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.